Nosso grupo organiza mais de 3.000 Séries de conferências Eventos todos os anos nos EUA, Europa e outros países. Ásia com o apoio de mais 1.000 Sociedades e publica mais de 700 Acesso aberto Periódicos que contém mais de 50.000 personalidades eminentes, cientistas de renome como membros do conselho editorial.

Periódicos de acesso aberto ganhando mais leitores e citações
700 periódicos e 15 milhões de leitores Cada periódico está obtendo mais de 25.000 leitores

Indexado em
  • Índice Copérnico
  • Google Scholar
  • Abra o portão J
  • Genâmica JournalSeek
  • Infraestrutura Nacional de Conhecimento da China (CNKI)
  • Biblioteca de Periódicos Eletrônicos
  • RefSeek
  • Universidade Hamdard
  • EBSCO AZ
  • OCLC – WorldCat
  • Biblioteca Virtual de Biologia (vifabio)
  • Publons
  • Fundação de Genebra para Educação e Pesquisa Médica
  • Euro Pub
  • ICMJE
Compartilhe esta página

Abstrato

Impact of Glasgow Prognostic Score on Advanced Cancer Patients in Palliative Care Settings: A Short Narrative Review

Tomofumi Miura and Yoshihisa Matsumoto

Advanced cancer patients gradually experience deterioration of their physical condition and symptoms. Prognostic information is quite important for patients, their caregivers and medical staff. The Glasgow Prognostic Score (GPS)/modified GPS (mGPS) is one of the objective prognostic indicators. This study aimed to review the prevalence of GPS/mGPS and its impact on the prognostic value, physical function, quality of life and symptoms, and cancer cachexia among cancer patients who had received supportive care without plan of any anti-tumor therapy. Six studies were identified. The increase in GPS/mGPS score was correlated with poor prognosis, poor performance status and weight loss in patients without anti-tumor therapy. However, no evidence about the correlation between GPS/mGPS and activities of daily living, quality of life and symptoms existed. More detailed classification of GPS/mGPS will be needed to adequately reflect the general conditions of advanced cancer patients who have received supportive care without plan of any anti-tumor therapy.